Font Size


Menu Style



International Primary Care Association

Clinical Focus Volume 4 N2

Changing Face of Endocrine Therapy for Breast Cancer Patients


The arrival of the aromatase inhibitors (AIs) has increased the options available for the management of postmenopausal women with hormone sensitive breast cancer. Where and when we should use them is however still controversial with the many trials of their use often having raised more questions than they have answered. There is no doubt that they have a role to play but it will be quite some time before we can confidently answer the questions of whether all post menopausal breast cancer patients should get them and if not all, then which patients should get them and for how long.

Additional Info

  • Authors: A Winter - Wright & J C Doughty
  • Keywords: Aromatase inhibitors, Endocrine therapy, Breast cancer
  • Login: Please login to view Full Text of the article
Read 1445 times Last modified on Monday, 26 November 2012 11:47

Post and reply comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.


BBC News Feed

Get in touch

Give us a call at
+44 207 637 3544

Email us at
info @


International Primary Care Association
73 Newman Street, London, W1T 3EJ